We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the ...

Fintel reports that on February 18, 2025, Barclays downgraded their outlook for Moderna (NasdaqGS:MRNA) from Overweight to ...

The article " Moderna: A Generational Opportunity for Investors in 2025 " first appeared on MarketBeat.

Q4 2024 Earnings Call Transcript February 14, 2025 Moderna, Inc. misses on earnings expectations. Reported EPS is $-2.91 EPS, ...

Bullish option flow detected in Moderna (MRNA) with 76,253 calls trading, 1.4x expected, and implied vol increasing almost 8 points to 77.82%.

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

The Montana House of Representatives on Wednesday voted overwhelmingly against House Bill 371, a measure that would have banned mRNA vaccines — used primarily in COVID-19 vaccines and booster shots — ...